Good morning, you're listening to Markets Desk.
SK Hynix is under pressure again, and the story cuts right to the heart of the AI trade. Despite posting a profit surge of five hundred fifty seven percent, shares slid sharply after earnings missed elevated expectations. Retail investors carrying heavy leverage and mounting fears around Chinese competition have amplified the selloff, though several analysts are holding their bullish calls, arguing the fundamentals remain intact.
Staying in the AI space, a quieter but telling signal emerged from Thinking Machines Lab, where cofounder Lilian Weng announced she is stepping away from her role citing stress and illness. It is a rare moment of candor from inside the industry, and it raises a question the sector has largely avoided — the human cost of building these systems at the pace the market demands is beginning to show.
On the biotech tape, Medicus Pharma dropped twelve percent after announcing the FDA issued a study may proceed notification for its SkinJect therapy in Phase two trials. Counterintuitively, the green light spooked investors — likely because the accompanying FDA recommendations signal a more demanding trial design ahead, raising the cost and timeline bar before any commercial path becomes clear.
That's the tape. Markets Desk, signing off the floor.
